Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.

According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.

Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.